About UsA clinical-stage biotechnology company focused on dermatology, wound care, and infectious disease.Read More News Releases Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis June 1, 2026 Read More Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model May 27, 2026 Read More Turn Therapeutics to Present at Jefferies Global Healthcare Conference 2026 May 19, 2026 Read More All News Releases
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis June 1, 2026 Read More
Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model May 27, 2026 Read More
